European ring test on the differentiation of wild-type Mycoplasma synoviae and the MS-H vaccine strains in clinical samples Authors: Cristina Martin Jimenez, Zsuzsa Kreizinger, Miklós Gyuranecz, Peter Cargill Published: 2026 ABSTRACT AbstractThe control and prevention of Mycoplasma (M.) synoviae infections have been significantly improved by the use of the MS-H live vaccine strain. This vaccine has been used globally for decades; therefore, many technical approaches have been published or commercialized for the differentiation of MS-H from field strains. However, key problems have been identified related to DIVA (differentiating infected from vaccinated animals) testing and monitoring of vaccination in many European laboratories and poultry farms. To address these concerns, the reliability of protocols for the differentiation of the MS-H vaccine and wild-type M. synoviae strains from clinical samples was assessed with the blind participation of 16 European laboratories using various techniques. Three pools of samples were sent to each laboratory containing equal amounts of either just MS-H vaccine or a field strain, or the mix of the two strains. The results highlight the challenges in live vaccine strain differentiation, as only 84.4 % (n = 38/45) of the samples were correctly identified. The present study also revealed a variability in the specificity between laboratories using the same technique, which indicates the influence of the operator and differences in the evaluation of raw data also. Sample pools containing both strains showed the highest failure rate in strain differentiation. Therefore, results obtained from laboratory testing should ideally be confirmed using an alternative appropriate technique and interpreted in consultation with the responsible veterinarian, taking into account the clinical history before making decisions with potentially high economic impact.Keywords: DIVA, Inter-laboratory comparison, MS-H, Mycoplasma synoviae, Unreliable molecular assay Introduction Infections with Mycoplasma (M.) synoviae are a major concern for the poultry industry, leading to respiratory diseases, infectious synovitis and eggshell-apex abnormalities in chickens and respiratory diseases in turkeys (Catania et al., 2010; Feberwee and Landman, 2010; Ferguson-Noel and Noormohammadi, 2013). This bacterium can be transmitted vertically through hatching eggs, or laterally by direct contact or indirect contact via the environment (Kleven, 2008; Stipkovits and Kempf, 1996). Neglected control programs, inappropriate biosecurity in the farms and large concentration of poultry in small geographic areas could result in the significant spread of mycoplasma infection. Control of the infections consists of three general aspects: eradication followed by prevention, vaccination or medication (Kleven, 2008). Historically, routine medication was commonplace, (and remains so in some countries), however since the introduction of live vaccination for M. synoviae, antibiotic use has declined significantly, and the prevalence of M. synoviae has also been substantially reduced (ter Veen et al., 2024). In situations where maintaining flocks free of mycoplasmosis is not feasible (e.g. in multi-age commercial layer farm) vaccination can be a viable option (Whithear, 1996). Currently, the MS-H strain (VaxSafe MS-H, Bioproperties Pty. Ltd., Registered in the European Union as MS-H vaccine, Pharmsure Veterinary Products Europe Ltd (PVPE)) is the only, globally available, live, attenuated vaccine against M. synoviae. The temperature sensitive (ts+) MS-H vaccine strain was developed by the chemical mutagenesis of an Australian field strain (86079/7NS) (Morrow et al., 1998), and it has been thoroughly examined, ultimately revealing the comparative whole genome sequence analysis with its parent strain and with a worldwide collection of reisolates (Klose et al., 2022; Zhu et al., 2018, 2019). As a live vaccine, the differentiation of the MS-H strain from field isolates is crucial for the surveillance of the vaccinated flocks. The vaccine colonizes the upper respiratory tract, slowing down colonization by field M. synoviae (Feberwee et al., 2017), and triggers a more effective immune response, activating both humoral and cellular immunity (Jones et al., 2006; Omotainse et al., 2022, 2023). Variable levels of serum antibody were observed in chickens after vaccination (Feberwee et al., 2017; Noormohammadi et al., 2002), and although improved detection of antibodies was achieved in vaccinated birds when MS-H specific recombinant antigen based assay was used (Noormohammadi et al., 2002), and probable strain-dependent antigen variations were described (Omotainse et al., 2025), no serological assays have been developed so far for the differentiation of MS-H vaccine strain and field strains. Consequently, molecular methods are preferred for post-vaccination monitoring and strain differentiation. The sensitivity and specificity of traditional molecular assays (such as Restriction Endonuclease Analysis, or Random Amplified Polymorphic DNA) for the differentiation of the MS-H vaccine strain from field isolates lag behind of that of novel approaches, they require the isolation of the strains and are labor intensive (Feberwee et al., 2005; Morrow et al., 1990). The genetic basis of the attenuation of the MS-H strain has been analyzed in several publications and many molecular biological assays have been developed (either published or commercialized as kits) for the identification of vaccine specific point mutations or sequences in one or in multiple genes (Dijkman et al., 2016, 2017; El-Gazzar et al., 2017; Hammond et al., 2009; Kreizinger et al., 2015, 2018; Shahid et al., 2013, 2014; Zhu et al., 2017, 2018, 2019). However, incongruencies were described in the case of some of these targets (obg, oppF, vlhA) making them unreliable when examined alone, and additional factors may hinder accurate detection of MS-H vaccine strain in a flock (Catania et al., 2016; Dijkman et al., 2014; Jeffery et al., 2007; Kreizinger et al., 2018). Moreover, interpretation of results and determination of a successful vaccination could be complicated further by the detection of potential coexistence of vaccine and field strain, which is not related to lack of efficacy of MS-H (Markham et al., 1998). This study aimed to assess the capability of various laboratories in the European Union (EU) to accurately identify M. synoviae strains from clinical samples - particularly in cases involving the concurrent presence of the MS-H vaccine strain and a field strain - using their respective diagnostic methodologies. The primary objectives were to evaluate the specificity of the techniques employed, to examine practical aspects such as inter-laboratory communication and result interpretation, and to identify potential issues affecting analytical reliability. Materials and methods Study design The control and prevention of M. synoviae infections have been significantly improved by the use of the MS-H vaccine strain; “MS-H vaccine” has been commercialised in the EU by PVPE who also provide support to end users and veterinarians. Over the past 12 years, key problems have been identified while providing technical support related to DIVA (differentiating infected from vaccinated animals) testing and monitoring of vaccination. To address these concerns, a blind multi-laboratory study was organised by PVPE, in collaboration with the specialised Mycoplasma laboratory (MolliScience) at the HUN-REN Veterinary Medical Research Institute in Budapest. The laboratories were selected for this study based on their diagnostic platform (i.e. offering MS-H DIVA test), without preliminary knowledge about their applied techniques and methodology. The participating 16 European laboratories examined the samples blindly, and were informed about the ring test after evaluation of the results. Accordingly, the study design ensured blinding with respect to the analytical methods employed, and all laboratories performed their work without knowledge of sample identities or study details. The study exclusively focused on testing and comparing the laboratories’ proficiency in detecting and differentiating the MS-H vaccine strain, without encompassing assessments of DNA extraction precision, accuracy of species identification, molecular assay efficiency, or downstream analytical performance. The study was designed to remain simple and focused, reflecting common field scenarios (typical farm-to-laboratory diagnostic pathway), to provide practical insights for veterinarians and farmers involved in MS-H vaccination monitoring. Thus, the sample set was constructed to represent clinical material from a vaccinated flock concurrently harbouring field M. synoviae, consisting of 3 swab pools: MS-H vaccine strain only, wild-type M. synoviae only, and a mixture of both. Each pool contained one swab spiked with a standardised concentration of the target culture (4.2 × 10⁶ CCU/mL for both MS-H and MYCAV261 aliquots). Confirmatory assays detected M. synoviae-specific DNA in all three swab pools (MS-H only pool: Ct 23.4–23.7; MYCAV261 only pool: Ct 24.5–24.8; mixed pool: Ct 23.3–23.5), and correctly identified the strains present in each pool. Negative controls and cultures of non-target species (e.g., M. gallisepticum) were not included. The field strain was selected based on its genetic characteristic, specifically its vlhA gene-based typing profile matching that of the MS-H vaccine strain. By using this field strain in the present study, we aimed to assess the extent to which vlhA gene-based typing is still employed for DIVA tests among diagnostic laboratories. However, other previously described, potentially revertible mutations, which may also cause discrepancies in strain differentiation, were not addressed in the current ring test. Strains The MS-H vaccine strain (MS-H vaccine, Bioproperties Pty. Ltd., Australia; LOT: MSH222251AG, manufactured on 17/08/2022, expiry date 17/08/2026) was provided by Pharmsure International Ltd. (Pharmsure Veterinary Products Europe Ltd., Bray, Republic of Ireland) in a 1000 dose bottle, which was maintained at −70°C until use. The wild-type Mycoplasma synoviae strain, MYCAV261 was isolated in 2016, Hungary from a single trachea swab sample from broiler turkeys. The MYCAV261 strain was characterized before based on the vlhA gene sequence and number of proline-rich repeats (PRR), the multi-locus sequence typing (MLST) and multiple locus variable number of tandem repeats assay (MLVA) (Kreizinger et al., 2018). MYCAV261 was proved to be a wild-type field isolate (MLST sequence type (ST) 26, (Dijkman et al., 2016); MLST ST 10, (El-Gazzar et al., 2017); MLVA genotype 33, (Kreizinger et al., 2018) showing identical vlhA sequence type (ST 2, PRR type C) (Dijkman et al., 2014) with the MS-H strain. Strain MYCAV261 was propagated in Frey’s medium (Frey et al., 1968), incubated at 37°C and aliquoted at color change and frozen at −70°C. The color changing units (CCU/ml) of an aliquot of strain MYCAV261 and the MS-H vaccine strain were determined by the broth micro-dilution method (Hannan, 2000). Sample preparation Three pools of 4 swabs were prepared for each of the 16 participating laboratories. In each swab pool, one swab contained the broth culture of the strains detailed earlier and 3 swabs were blank. Swab samples were prepared by adding 30 µl of the MS-H vaccine strain only, 30 µl of the MYCAV261 wild-type strain only or a mixture (30-30 µl) of the MS-H vaccine and MYCAV261 wild-type strains. All swab samples were prepared at once, using the same aliquot of MS-H vaccine strain and of the MYCAV261 isolate. The concentrations of mycoplasma broth cultures were adjusted in phosphate buffered saline to 104 CCU/ml. The rationale behind the concentration of each strain and the inoculation of only one of the 4 swabs was to replicate the likely concentrations of M. synoviae that would be present in swabs from clinical cases. Negative controls and cultures of non-target species (e.g., M. gallisepticum) were not included in the study design, as the study aimed to mimic routine field diagnostic submissions under practical conditions rather than perform a comprehensive analytical validation of assay specificity. However, the absence of such controls represents a limitation of the study and should be considered when interpreting the findings. Although the ‘mixed’ swabs contained equal amounts of MS-H and field strains, unlike clinical samples where one strain often predominates; this design should have favored, not limited, the detection of both strains. One set of swab samples was submitted for confirmatory assays after freezing at −20°C and thawing at room temperature (25°C). Confirmatory assays included DNA extraction from the pools of swabs with Chelex 100 (Bio-Rad Laboratories, CA, USA), M. synoviae species-specific PCR (Raviv and Kleven, 2009), Kylt® MS-H DIVA commercial kit (SAN Group Biotech Germany GmbH, Höltinghausen, Germany) and mismatch amplification mutation assay (MAMA) targeting a point mutation in the recA gene (Yvon et al., 2019) to detect and differentiate MS-H vaccine strain and wild-type M. synoviae strains. Sample distribution All swab preparation and sample handling procedures were performed under sterile conditions in accordance with standard Good Laboratory Practice (GLP) and routine molecular laboratory practices to minimise the risk of cross-contamination. The pools of swab samples were stored at −20°C after preparation and transferred to the PVPE centre on ice within 24 h of shipment for distribution. The samples were assigned to 16 European laboratories which participated in the test blindly. The samples were submitted for routine diagnostic tests for the identification of M. synoviae and differentiation between the MS-H vaccine and field strains, shipped via air cargo within 24 h delivery, without cooling. Participating laboratories Laboratories were selected for the ring test according to their diagnostic services (i.e. providing MS-H DIVA). Samples were sent to the selected laboratories through PVPE as clinical specimens, and results were obtained in the form of laboratory reports. Participating laboratories were notified of their involvement in the ring test after their reports had been submitted, and supplementary information on DIVA testing was requested when not provided. The evaluation of laboratory steps preceding (DNA extraction, species identification) or following (analysis of raw data) the DIVA tests was beyond the scope of this study. Results The preliminary broth micro-dilution assays showed 4.2E+06 CCU/ml in both MS-H and MYCAV261 aliquots. Confirmatory assays detected the presence of M. synoviae specific DNA in all three swab pools (pool MSH only: cycle threshold value (ct) 23.4-23.7, pool MYCAV261 only: ct 24.5-24.8, pool ‘mix’: ct 23.3-23.5), and correctly identified the strains in each pool. Two kinds of commercial kits and 5 distinct PCR based methods (in-house development or adapted from publications or recommendations) were used for strain differentiation by the 16 participating laboratories (Table 1, Table 2). The Kylt® MS-H DIVA commercial kit (SAN Group Biotech Germany GmbH, Höltinghausen, Germany) was used by 8 laboratories and the AdiavetTM MS-H DIVA Fast Time kit (Bio-X Diagnostics, S.A.R.L. ADIAGENE, Ploufragan, France) was applied by 2 laboratories. Three laboratories performed the strain differentiation based on SNP identification: 2 assays were adapted from the publications of Dijkman and co-workers (2017) and Yvon and co-workers (2019); and an in-house method was based on SNPs in the obg and rpo genes identified during the comparison of the MS-H vaccine strain and its parent strain (Zhu et al., 2019). One laboratory used the sequence analysis of the vlhA gene (Hammond et al., 2009), and one laboratory followed the recommendations of the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (OIE, 2021) with sequencing the vlhA gene (Hammond et al., 2009) followed by MLST analysis (El-Gazzar et al., 2017). Table 1Detailed results of the ring-test.Table 1 dummy alt textLaboratory No.Tests for the differentiation of MS-H vaccine strain and wild-type M. synoviaeResults for the wild-type M. synoviae (MS) sampleResults for the MS-H vaccine sampleResults for the mix of wild-type M. synoviae (MS) and MS-H vaccine sample1Kylt® MS-H DIVAwild-type MSCt 25.1MS-H30.8MS-H & wild-type MSCt 27.7 & Ct 30.82Kylt® MS-H DIVAwild-type MSCt 26.7MS-HCt 28.5wild-type MSCt 26.327Kylt® MS-H DIVAwild-type MSCt 23.1MS-HCt 23.6MS-H & wild-type MSCt 24.3 & Ct 21.59Kylt® MS-H DIVAwild-type MSaCt 24.0MS-HCt 27.3MS-H & wild-type MSCt 22.0 & Ct 23.410Kylt® MS-H DIVAMS-H & wild-type MSCt 31.0 & Ct 25.0MS-HCt 31.9MS-H & wild-type MSCt 28.0 & Ct 24.713Kylt® MS-H DIVAwild-type MSCt 25.7MS-HCt 27.0wild-type MSCt 25.214Kylt® MS-H DIVAwild-type MSCt 26.2MS-HCt 26.0MS-H & wild-type MSinterferenceb & Ct 25.715Kylt® MS-H DIVAwild-type MSCt 23.8MS-HCt 28.4MS-H & wild-type MSCt 28.1& Ct 23.73Adiavet™ MS-H DIVA Fast Timewild-type MSCt 21.7MS-HCt 23.1MS-H & wild-type MSCt 24.2 & Ct 25.38Adiavet™ MS-H DIVA Fast Timewild-type MSCt 26.1MS-HCt 27.6MS-H & wild-type MSCt 27.0 & Ct 24.26SNP based PCR (obg and rpo genes, in-house method)wild-type MSCt 30.0MS-HCt 32.0MS-H & wild-type MSCt 34.0 & Ct 29.012sent samples to laboratory No. 6 for genotypingnegativenegativewild-type MSCt 32.011SNP based qPCR (obg gene, Dijkman et al., 2017)wild-type MSCt 24MS-HCt 26wild-type MSCt 2416SNP based MAMA (recA gene, Yvon et al., 2019)wild-type MSCt 23.3MS-HCt 24.5MS-H & wild-type MSCt 22.24vlhA gene sequencing (Hammond et al., 2009) and MLST (El-Gazzar et al., 2017)wild-type MS (ST10)n.a.MS-H (ST43)n.a.wild-type MS (ST10)n.a.5vlhA gene sequencing (Hammond et al., 2009)MS-HCt 27.7MS-HCt 29.7MS-HCt 26.6Abbreviations: MLST= multi locus sequence typing, DIVA= differentiation of infected from vaccinated animals, SNP= single nucleotide polymorphism, MAMA= mismatch amplification mutation assay, n.a.= not applicable.avaccine detected above cut-off value (cut-off: Ct 36, sample: Ct 36.4).binhibition due to possible interference; incorrect results are in bold. Detailed results of the ring-test. Abbreviations: MLST= multi locus sequence typing, DIVA= differentiation of infected from vaccinated animals, SNP= single nucleotide polymorphism, MAMA= mismatch amplification mutation assay, n.a.= not applicable. vaccine detected above cut-off value (cut-off: Ct 36, sample: Ct 36.4). inhibition due to possible interference; incorrect results are in bold. Table 2Target genes and mutations of the assays applied during the ring-test.Table 2 dummy alt textTests for the differentiation of MS-H vaccine strain and wild-type M. synoviaeNumber of laboratories using the assayTargeted genesNucleotide positions of targeted mutationsKylt® MS-H DIVA8obg180903 - 181517 and181470 - 182113aAdiavet™ MS-H DIVA Fast Time2not availablebnot availablebSNP based PCR (obg and rpo genes, in-house method)2obgrponot availablebSNP based qPCR (obg gene, Dijkman et al., 2017)1obg180903 - 181517 and 181470 - 182113aSNP based MAMA (recA gene, Yvon et al., 2019)1recA667974avlhA gene sequencing (Hammond et al., 2009) and MLST (El-Gazzar et al., 2017)1vlhA49 - 421cadk682056 - 682691aatpG458197 - 159066aefp487039 - 487599agmk125501 - 126097anagC218237 - 219097appa154803 - 155348arecA667056 - 668619avlhA gene sequencing (Hammond et al., 2009)1vlhA49 - 421canucleotide numbering of genomic region of strain MS53 (GenBank Accession Number: AE017245).binformation not available due to intellectual property constraints.cnucleotide numbering of the vlhA gene of strain WVU1853 (GenBank Accession Number: AF0356. Target genes and mutations of the assays applied during the ring-test. nucleotide numbering of genomic region of strain MS53 (GenBank Accession Number: AE017245). information not available due to intellectual property constraints. nucleotide numbering of the vlhA gene of strain WVU1853 (GenBank Accession Number: AF0356. Only one laboratory failed to detect specific DNA in 2 out of the 3 sample pools (samples containing MS-H vaccine only and the wild-type strain only), however, in this case the samples were forwarded to another laboratory for typing (transporting conditions unknown), thus the results of this laboratory were excluded from the analyses. All 3 sample types (MS-H only, wild-type M. synoviae only, mix of MS-H and wild-type M. synoviae strains) were correctly identified by nine laboratories (7 of them used commercial kits and 2 of them used single nucleotide polymorphism (SNP) based PCR methods), with varying sensitivity (Table 1, Table 3). The sample pool containing MS-H vaccine strain only was identified correctly by 15 laboratories, while the sample pool with the wild-type M. synoviae strain only was recognized by 13 laboratories. Evaluation of the sample pool containing both strains resulted the highest failure rate with the detection of only one strain in 5 laboratories. Table 3Summarized data of the accurate and inaccurate results from the ring-test.Table 3 dummy alt textData typeCorrectly identifiedInaccurately identifiedTotal No. evaluatedaPercentage of correct results (%)all samplesall laboratories3874584.4commercial kitsb2733090.0all three poolsall laboratories961566.7commercial kits731070.0MS-H only poolall laboratories15015100.0commercial kits10010100.0wild-type MS only poolall laboratories1321586.7commercial kits911090.0MS-H and wild-type MS poolall laboratories1051566.7commercial kits821080.0 Summarized data of the accurate and inaccurate results from the ring-test. Ten laboratories used commercial kits for strain differentiation, of which 7 laboratories correctly evaluated the results. One laboratory detected mixed infection in the pool containing wild-type M. synoviae strain only and another one also commented that mixed infection with the MS-H vaccine strain was suspected due to MS-H specific signal detection a little above the cut-off value. In one case, the mixed pool was identified by the detection of possible interference (no definite result could be read) and not by specific signal. Two laboratories detected only the wild-type M. synoviae strain in the pool containing both strains. Three laboratories applied PCR based assays for the identification of strain specific SNPs, out of which 2 laboratories correctly interpreted all results. One laboratory (targeting SNPs in the obg gene) identified only the wild-type M. synoviae strain in the pool containing mixed inoculates. Two laboratories performed strain differentiation based on sequence analysis. The laboratory using the evaluation of the vlhA gene only failed to distinguish the wild-type strain from the vaccine and reported the presence of MS-H only in all three pools. The laboratory which used MLST after vlhA typing correctly identified the wild-type strain and the vaccine in the single-strain pools, but failed to detect the MS-H vaccine in the mixed pool. Discussion Previously, an interlaboratory comparison of ability to detect M. synoviae and M. gallisepticum specific DNA was assessed involving 13 laboratories from 5 countries. The participating laboratories either used commercial kits or in-house methods, with various DNA extraction techniques, revealing differences in the results even when the same kits were in use (Hess et al., 2007). The present study assessed the reliability of protocols for the detection and differentiation of the MS-H vaccine and wild-type M. synoviae strains from clinical samples with the blind participation of 16 European laboratories, to gain further insights in the diagnosis of avian mycoplasmosis. A limitation of this study is the low number of participating laboratories, which were selected in a blinded manner based solely on their known offer of MS-H DIVA testing, without prior knowledge of the methodologies they employed. Also, the sample set was intentionally designed to be simple and focused to ensure a realistic field simulation; however, this approach did not include control points such as a no-template control or assessments of concurrent infections, which are considered additional limitations of the study. Furthermore, among all the known mutations targeted in DIVA tests the present study addressed coincidental matching of field strain profiles with that of the MS-H strain solely in vlhA gene-based typing. However, despite the limited scope, the study revealed notable variability in results, even among laboratories using the same commercial kits. This raises concerns about repeatability and reliability, which are supposed to be highly relevant for end users, particularly considering the economic implications of MS-H vaccination, and the gained information is also important for laboratories to improve their diagnostic services. To our knowledge, this is the first study to assess how EU laboratories perform MS-H DIVA testing in practice. Although not designed to extrapolate to other jurisdictions, the findings underscore broader, globally relevant challenges in diagnostic consistency, such as the selection and continuous refinement of suitable methodologies, interpretation of test results including those of commercial kits, the rigorous validation of the used assays and application of confirmatory testing. In clinical samples, it is not uncommon to detect the presence of wild M. synoviae strain together with MS-H in MS-H vaccinated birds that are clinically normal. This finding aligns with field observations (ter Veen et al., 2024) showing that successive MS-H vaccination cycles reduce the risk of M. synoviae infection, reducing M. synoviae incidence, by lowering shedding and transmission rates of the wild strain; the results also indicate that successive MS-H vaccination may contribute to elimination of the wild strain, although further research is needed to confirm this under different field conditions (ter Veen et al., 2024). While bacterial loads can vary widely in practice, the amount of M. synoviae cultures on to each swab was selected to approximate the levels typically expected in clinical field samples and to ensure detectability by standard DNA extraction and PCR methods. The study intended to provide a realistic yet consistent template for evaluating PCR performance, for which the same amount of the same of batch of bacterial cultures of standardized CCUs were applied on the spiked swabs. As such specificity of the results from each laboratory could be evaluated, without specifically assessing the analytical sensitivity of the PCR techniques employed, as this can be influenced by the reliability of the DNA extraction process from the submitted samples. Three pools of samples were sent to each laboratory, containing equal amounts of either the MS-H vaccine strain, the MYCAV261 field strain, or a mixture of both strains. The results highlight the challenges in live vaccine strain differentiation, as only 60.0 % (n = 9/15; Table 2) of the laboratories managed to correctly identify all 3 sample pools, reporting the true genotype(s) in 84.4 % (n = 38/45; Table 2) of the samples. The MS-H live vaccine has been successfully used globally for decades, therefore its differentiation from field strains has been a focus of developing diagnostic tools for a long time and many approaches have been published or commercialized for this purpose. The comparative analysis of the whole genome sequences of the MS-H vaccine strain, its parent strain (Australian field strain 86079/7NS), the type strain (WVU-1853) and a Brazilian field strain (MS53) revealed 30 unique SNPs in the MS-H vaccine strain (Zhu et al., 2019). Based on the provided information in the present study (Table 2), 3 of the applied 6 approaches have the potential to target one of these unique SNPs. Nevertheless, given the high genetic variability of mycoplasmas (Razin et al., 1998), inclusion of a larger number of strains in the comparisons would likely result in a reduced number of unique SNPs. Therefore, it should be appreciated, that no technique can be regarded as 100 % definitive in terms of strain differentiation, as it is impossible to validate techniques with all field strains present globally. Therefore, when using PCR based assays for the differentiation of MS-H, users must appreciate that the techniques may provide a false result in terms of strain identification. Due to the selection criteria (i.e., diagnostic platform provides MS-H DIVA test) and the blinded nature of the study design regarding the assays used, the current study does not allow for robust conclusions regarding the relative performance of commercial kits versus in-house methods. Nonetheless, our findings show that the majority of the examined EU laboratories currently rely on commercial kits (Table 1). The present study revealed a variability in the results between laboratories even using the same technique, which suggests an influence of the operator and/ or differences in the evaluation of raw data. The commercial kits used in the present study are based on the detection of strain specific SNPs. Eight laboratories submitted the samples for the Kylt test, out of which 2 laboratories detected only the wild-type strain in the pool containing both strains. The cycle threshold values of the samples were in accordance with the ones detected in other laboratories using the same kit, therefore difference in the quality of the samples or in the amount of DNA extracted can be ruled out. In these cases, potential issues with sample handling or interpretation of results are suggested, with lower sensitivity or interference in their testing environment. Another 2 laboratories using Kylt test reported or commented on the presence of MS-H specific signals in the pool containing only the wild-type strain. This finding may indicate a possible cross-reaction or contamination (either at sample preparation or in the laboratory) issue. Also, there might be a difference in evaluation of results of commercial kits. Nevertheless, 70.0 % (n = 7/10; Table 3) of the laboratories using commercial kits (Kylt test in 8 cases, AdiaVet test in 2 cases) reported correct results for all sample pools, and 90.0 % (n = 27/30; Table 3) of the samples were identified by the commercial kits, demonstrating that well developed assays can be effective if properly validated and used under optimal conditions. The laboratories using SNP based assays either adapted their methods from previous publications or developed the techniques themselves, and few matches can be detected among them based on the provided data in the present study. Two of the 3 laboratories using SNP based assays clearly identified all 3 sample pools, while the third laboratory missed the detection of the MS-H strain in the mixed pool. Two laboratories follow protocols of sequencing for strain identification and the differentiation of MS-H vaccine strain. Both laboratories performed genotyping based on the vlhA gene, a technique which has been identified unsuitable for distinguishing the MS-H vaccine strain from certain field isolates (Catania et al., 2016; Dijkman et al., 2014; Jeffery et al., 2007; Kreizinger et al., 2018). The wild-type strain MYCAV261, with known same genotype by vlhA typing as the MS-H vaccine, was used on purpose for the present ring-test to assess the extent of the use of this technique. While vlhA gene-based typing confirmed the profile of the MS-H vaccine strain as expected, none of the other used techniques misidentified the wild-type strain as the vaccine strain. This finding underscores the importance of refinement of diagnostic tools according to latest publications. Although this study was restricted to 2 strains, future work should be expanded to encompass MS-H vaccine variants and additional target mutations utilized in other DIVA assays to more accurately determine the reliability of available diagnostic methods. While such analyses may extend beyond the traditional framework of ring tests, they could be incorporated into laboratory validation protocols to assess DIVA assay performance using well-characterized region-specific field strains and vaccine reisolates. One of the laboratories using sequencing for strain differentiation submitted the samples for MLST after vlhA typing. Thus, the identification of the wild-type strain was successful, yet they failed to detect the MS-H strain in the mixed sample. In this case, limitations may have occurred assay sensitivity, during sequencing, or at any stage of the multi-step process (including sample preparation, transport, storage, extraction, amplification) or interpretation protocols. While MLST sequence typing on the PubMLST online platform is automated and not subject to user interpretation, the analyses of raw sequence data or upstream processing steps may vary between laboratories and influence the final output. However, interpretation protocols were not assessed in the present study. The fact that the evaluation of the sample pools containing both strains resulted the highest failure rate (66.7 % of the mixed samples, 86.7 % of the wild-type only samples and 100 % of the MS-H only samples were correctly reported, not counting the cases where no DNA was detected; Table 3) raises further questions. The swabs were loaded with equal amounts of MS-H and field strain cultures of standard CCUs in the ring-test, while in a mixed field sample it would be likely that the levels of each strain are very different, which could further add doubt over the results. Nevertheless, the majority of laboratories that failed to detect both strains in the mixed samples reported the presence of the field strain (n = 5/6), which is of critical importance in diagnostic practice and in monitoring vaccination status. One of the laboratories could not detect any specific DNA in two sample pools, which could question the sample handling (either during preparation or in the laboratory; note that only one swab was inoculated with the given cultures and 3 swabs were left blank in the pools), stability of DNA during transport (in the original sample, and note that DNA extracts were transported to another laboratory for typing), effectiveness of DNA extraction, or sensitivity of the used assay. The false results observed may indicate insufficient sensitivity or issues with the SNP detection process also. Therefore, when using PCR based assays for the differentiation of MS-H, users must appreciate that the techniques may provide a false result in terms of strain identification and/or presence/absence of M. synoviae also. In differentiating the MS-H live vaccine strain, failures may arise not only from limitations in the applied methodologies (e.g., DNA extraction and molecular assays) but also from procedural issues such as sample mix-ups or clerical errors during data transcription. In the present trial there is a clear indication that the same technique in different laboratories will give different results. A limitation of the study is that participating laboratories were not classified by expertise or testing volume, and complete methodological details were not available from all laboratories due to proprietary restrictions. Besides, sample handling, DNA extraction, contamination issues and interpretation of the results all influence the final results, which are therefore advised to be confirmed by another laboratory (preferably using different techniques) and discussed with the responsible veterinarian, taking into account the clinical history before making decisions with high economic impact. To the authors’ knowledge, comparable international inter-laboratory ring trials specifically evaluating MS-H DIVA testing have not yet been published, limiting direct regional comparison of diagnostic performance. Moreover, the findings of this study highlight the difficulty of establishing a universal gold-standard approach for MS-H DIVA testing, particularly in mixed-strain samples. Consequently, diagnostic results should be interpreted on a case-by-case basis, considering vaccination history, clinical presentation, and local epidemiological context. CRediT authorship contribution statement Cristina Martin Jimenez: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Zsuzsa Kreizinger: Writing – review & editing, Writing – original draft, Project administration, Methodology, Investigation, Formal analysis. Miklós Gyuranecz: Writing – review & editing, Supervision, Methodology, Funding acquisition. Peter Cargill: Writing – review & editing, Supervision, Conceptualization. Disclosures The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Zsuzsa Kreizinger reports financial support was provided by Ministry of Culture and Innovation of Hungary. Miklos Gyuranecz reports was provided by Ministry of Culture and Innovation of Hungary. Zsuzsa Kreizinger reports financial support was provided by National Recovery Fund budget estimate. Miklos Gyuranecz reports financial support was provided by National Recovery Fund budget estimate. Cristina Martin Jimenez reports a relationship with Pharmsure Veterinary Products Europe Ltd that includes: employment. Peter Cargill reports a relationship with Pharmsure Veterinary Products Europe Ltd that includes: employment. As per my ethical obligation as a researcher, I am reporting that Pharmsure Veterinary Products Europe Ltd has a financial and business interests in the product, MS-H Vaccine. This research is sponsored by Pharmsure Veterinary Products Europe Ltd to address testing and monitoring issues when differentiating infected from vaccinated animals in relation to Mycoplasma synoviae. Therefore, this research does not involve a conflict of interest, as its only purpose is informative and will not lead to any commercial impact on MS-H vaccine sales. The authors declare no involvement in the development, commercialisation, or income generation of any of the commercial diagnostic kits evaluated in this study. The authors’ have no financial or personal relationships with the manufacturers of these kits that could influence the findings. All relevant interests have been fully disclosed to Elsevier, and an approved plan is in place for managing any potential conflicts related to the study’s sponsorship. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements Z. Kreizinger and M. Gyuranecz were supported in part by the Project no. RRF-2.3.1-21-2022-00001 which has been implemented with the support provided by the Recovery and Resilience Facility (RRF), financed under the National Recovery Fund budget estimate, RRF-2.3.1-21 funding scheme and the support provided by the Ministry of Innovation and Technology of Hungary (legal successor: Ministry of Culture and Innovation of Hungary) from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA-01 funding scheme of the National Research, Development and Innovation Office. Footnotes Scientific section: Molecular biology References